First Quarter Earnings of $2.23 Per Diluted Common Share Resulting from Strong Asset Level Performance and Continued Acquisition Integration ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) (Atlanticus, the Company, we, our or us), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of Everyday Americans, today announced its financial results for the first quarter ended March 31, 2026. An accompanying earnings presentation is available in the Investors section of the Company’s website at www.atlanticus.com or by clicking here. Financial and Operating Highlights First Quarter 2026 Highlights (all comparisons to the First Quarter 2025)Total operating revenue and other income increased 97.0% to $679.5 million Managed...

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) — FTAI Infrastructure Inc. (NASDAQ:FIP) (the “Company” or “FTAI Infrastructure”) today reported financial results for the first quarter 2026. The Company’s consolidated comparative financial statements and key performance measures are attached as an exhibit to this press release. Business HighlightsAnnounced agreement on April 30, 2026, to sell Long Ridge to MARA Holdings, Inc. for $1.52 billion transaction value. At closing of the sale, FIP will immediately eliminate $1.16 billion of Long Ridge debt and use net proceeds to repay approximately $300 million of debt at the FIP parent level, resulting in lower interest expense and higher free cash flow going forward. Reported $70.6 million of Adjusted EBITDA for the first quarter of 2026. Long Ridge first quarter results were impacted by a...

– Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) – – Enrollment of 40 patients in Varseta-M Dose Optimization completed; data update expected in 2H 2026 to inform monotherapy dose selection and potential registrational trial in late line CRC – – Varseta-M Phase 1 study evaluating combination with bevacizumab is ongoing with initial data expected by 1H 2027; Phase 1/2 Varseta-M chemotherapy combination study to be initiated in 2H 2026 – – Initiation of Phase 1 expansion cohort(s) in non-CRC indications planned for 2H 2026 – – Company to host conference call today at 5 p.m. ET / 2 p.m. PT – SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) — CytomX...

Dallas, Texas, May 07, 2026 (GLOBE NEWSWIRE) — Valhi, Inc. (NYSE: VHI) reported net income attributable to Valhi stockholders of $2.0 million, or $.07 per share, in the first quarter of 2026 compared to net income of $16.9 million, or $.59 per share, in the first quarter of 2025. Net income attributable to Valhi stockholders decreased in the first quarter of 2026 compared to the first quarter of 2025 primarily due to lower operating results from the Chemicals Segment, partially offset by higher operating income from the Component Products and the Real Estate Management and Development Segments. The Chemicals Segment’s net sales of $509.8 million in the first quarter of 2026 were $20.0 million, or 4%, higher than in the first quarter of 2025. The Chemicals Segment’s net sales increased in the first quarter of 2026 compared to the...

– Q2 Sales increase 33% to $309 Million – Q2 Entered Orders increase 42% to $378 Million – Q2 GAAP EPS from Continuing Operations increases 26% to $1.29 – Q2 Adjusted EPS from Continuing Operations increases 63% to $1.91 – St. Louis, May 07, 2026 (GLOBE NEWSWIRE) — ESCO Technologies Inc. (NYSE: ESE) (ESCO, or the Company) today reported its operating results for the second quarter ended March 31, 2026 (Q2 2026).     Operating HighlightsQ2 2026 Sales increased $78 million (33.5 percent) to $309 million compared to $232 million in Q2 2025. Q2 2026 organic sales increased $30 million (12.8 percent) and Maritime contributed $48 million (20.7 percent) of revenue growth in the quarter.    Q2 2026 GAAP EPS from Continuing Operations increased 26.5 percent to $1.29 per share compared to $1.02 per share in...

Quarterly revenue of $1.378 billion and adjusted EBITDA of $166 million; GAAP income of $1.59/share and adjusted EPS of $2.10 DALLAS, May 07, 2026 (GLOBE NEWSWIRE) — AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2026 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q1 2026 % Change Q1 2025Revenue $1,378.4 100%Gross profit $368.8 86%Net income $62.2 nmGAAP diluted EPS $1.59 nmAdjusted diluted EPS* $2.10 366%Adjusted EBITDA* $166.1 159%     * See “Non-GAAP Measures” below for a discussion of our use of non-GAAP items and the table entitled “Non-GAAP Reconciliation Tables” for a reconciliation of non-GAAP items. Business...

First Quarter Financial Highlights:Total revenues decreased $12.5 million year over year to $410.5 million. On an organic basis*, revenues decreased $8.6 million year over year, or 2.1% Material Handling revenues decreased $7.4 million year over year to $150.5 million, while Construction Equipment and Master Distribution revenues decreased a combined $1.8 million year over year to $261.4 million. On an organic basis*, Material Handling and Construction Equipment segment revenues were down $4.7 million and $0.3 million year over year, respectively Material Handling and Construction Equipment segments new and used equipment sales gross profit margins both remained stable year over year at 19.6% and 11.7%, respectively, and improved notably on a sequential basis Service gross profit percentage increased 10 basis points year over year to...

AUDUBON, Pa., May 07, 2026 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026:Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis. Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis. GAAP net income for the quarter was $124.3 million. GAAP diluted earnings per share (“EPS”) was $0.90, an increase of 66.6%. Non-GAAP diluted EPS was $1.12, an increase of 64.7%.“We’re off to a strong start in 2026 with 27% overall revenue growth and record first quarter earnings. Organic revenue grew over 13%, driven by share gains and procedural volume...

Net Premiums Earned Growth of 28% for Q1 2026 | Direct Premiums Written Growth1 of 20% for Q1 2026 Q1 GAAP Net Combined Ratio of 112.0% Driven by Eleven Winter Catastrophe Events in the Northeast U.S.Q1 Underlying Combined Ratio1 Improved 5.1 Points to 88.3%Q1 Diluted Net Loss Per Share of $0.40 | Q1 Diluted Operating Net Loss Per Share1 of $0.35 Company Reaffirms 2026 Full Year Guidance Management to Host Conference Call Tomorrow at 8:30 a.m. Eastern Time KINGSTON, N.Y., May 07, 2026 (GLOBE NEWSWIRE) — Kingstone Companies, Inc. (Nasdaq: KINS) (“Kingstone” or the “Company”), a regional property and casualty insurance holding company, today announced its financial results for the first quarter ended March 31, 2026. The Company has also provided an investor presentation that can be accessed through the News & Events/Presentations...

Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to informregistrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX), clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “We filed a request to meet with the Food and Drug Administration’s Division of Psychiatry to discuss our plans for a registrational study in people with dementia with Lewy body (DLB) psychosis,” stated Lisa Ricciardi, Cognition’s president and CEO. “We recently received our meeting invitation for May 20, 2026 and we are looking forward to a productive conversation so we can...